Literature DB >> 17141659

FOXM1c and Sp1 transactivate the P1 and P2 promoters of human c-myc synergistically.

Inken Wierstra1, Jürgen Alves.   

Abstract

We have previously shown that FOXM1c transactivates the c-myc P1 and P2 promoters via their TATA-boxes by a new transactivation mechanism, namely by directly binding to the P1 and P2 TATA-boxes and to TBP, TFIIA, and TFIIB. We now confirm this surprising mechanism by demonstrating that FOXM1c transactivates the human c-myc P1 and P2 promoters synergistically with Sp1, a transcription factor known to bind and transactivate these two promoters. This synergism requires the P1 or P2 TATA-boxes as well as the respective Sp1-binding sites. Moreover FOXM1c binds directly to Sp1. Cooperative DNA binding, if it should occur, is not sufficient for synergism of Sp1 and FOXM1c at P1, but their contacts to multiple components of the basal transcription complex (TFIID, TFIIA, TFIIB) seem to be essential. However, FOXM1c does not synergize with Sp1 if it transactivates via its conventional binding site.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141659     DOI: 10.1016/j.bbrc.2006.10.151

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Forkhead box M1 transcription factor: a novel target for cancer therapy.

Authors:  Zhiwei Wang; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Cancer Treat Rev       Date:  2009-12-22       Impact factor: 12.111

Review 2.  Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy.

Authors:  Li Gu; Han-Min Liu
Journal:  World J Pediatr       Date:  2019-06-12       Impact factor: 2.764

3.  Polo-like kinase 1-mediated phosphorylation of Forkhead box protein M1b antagonizes its SUMOylation and facilitates its mitotic function.

Authors:  Jinglei Zhang; Chengfu Yuan; Jianguo Wu; Zeinab Elsayed; Zheng Fu
Journal:  J Biol Chem       Date:  2014-12-22       Impact factor: 5.157

Review 4.  Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Authors:  Xin Song; Samuel Selorm Fiati Kenston; Jinshun Zhao; Danting Yang; Yuanliang Gu
Journal:  Med Oncol       Date:  2017-02-08       Impact factor: 3.064

5.  The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression.

Authors:  Hisaki Hayashi; Hideto Sano; Seungwoon Seo; Tsutomu Kume
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

6.  Transcription factor interactions mediate EGF-dependent COX-2 expression.

Authors:  Kaiming Xu; Hui-Kuo G Shu
Journal:  Mol Cancer Res       Date:  2013-05-01       Impact factor: 5.852

7.  Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells.

Authors:  Zhongqiu Xie; Guixiang Tan; Miao Ding; Difei Dong; Tuanhui Chen; Xiangxian Meng; Xiaoqin Huang; Yongjun Tan
Journal:  Nucleic Acids Res       Date:  2010-08-11       Impact factor: 16.971

8.  Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence.

Authors:  D R Littler; M Alvarez-Fernández; A Stein; R G Hibbert; T Heidebrecht; P Aloy; R H Medema; A Perrakis
Journal:  Nucleic Acids Res       Date:  2010-03-31       Impact factor: 16.971

9.  FOXM1 binds directly to non-consensus sequences in the human genome.

Authors:  Deborah A Sanders; Michael V Gormally; Giovanni Marsico; Dario Beraldi; David Tannahill; Shankar Balasubramanian
Journal:  Genome Biol       Date:  2015-06-23       Impact factor: 13.583

10.  FOXM1 confers acquired cisplatin resistance in breast cancer cells.

Authors:  Jimmy M-M Kwok; Barrie Peck; Lara J Monteiro; Helma D C Schwenen; Julie Millour; R Charles Coombes; Stephen S Myatt; Eric W-F Lam
Journal:  Mol Cancer Res       Date:  2010-01-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.